|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
JP4939926B2
(ja)
*
|
2003-02-14 |
2012-05-30 |
アノシス・インコーポレーテッド |
抗体を生成し抗体レパートリーをスクリーニングするための方法とコンパウンド
|
|
AU2004254600A1
(en)
|
2003-06-26 |
2005-01-13 |
Lifesensors, Inc. |
Methods and compositions for enhanced protein expression and purification
|
|
CA2556752C
(en)
|
2004-02-23 |
2016-02-02 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
CA2627105A1
(en)
|
2005-10-26 |
2007-05-03 |
Protelix, Inc. |
Influenza combinatorial antigen vaccine
|
|
CN101790380B
(zh)
|
2007-02-07 |
2013-07-10 |
加利福尼亚大学董事会 |
合成tlr激动剂的缀合物及其应用
|
|
US8426565B2
(en)
|
2007-08-30 |
2013-04-23 |
Walter And Eliza Hall Institute Of Medical Research |
Dendritic cell marker and uses thereof
|
|
WO2009030996A1
(en)
|
2007-09-05 |
2009-03-12 |
Coley Pharmaceutical Group, Inc. |
Triazole compounds as toll-like receptor (tlr) agonists
|
|
US9421254B2
(en)
|
2007-09-24 |
2016-08-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunostimulatory combinations of TLR ligands and methods of use
|
|
US9370558B2
(en)
|
2008-02-13 |
2016-06-21 |
President And Fellows Of Harvard College |
Controlled delivery of TLR agonists in structural polymeric devices
|
|
WO2010014913A1
(en)
|
2008-08-01 |
2010-02-04 |
Ventirx Pharmaceuticals, Inc. |
Toll-like receptor agonist formulations and their use
|
|
CA2777198C
(en)
|
2009-10-06 |
2018-07-24 |
Panacela Labs, Inc. |
Use of toll-like receptor and agonist for treating cancer
|
|
EP3195868A3
(en)
|
2010-10-01 |
2017-08-02 |
VentiRx Pharmaceuticals, Inc. |
Therapeutic use of a tlr agonist and combination therapy
|
|
PL3892295T3
(pl)
|
2011-05-24 |
2023-07-24 |
BioNTech SE |
Zindywidualizowane szczepionki przeciwnowotworowe
|
|
WO2013053008A2
(en)
|
2011-10-14 |
2013-04-18 |
The Walter And Eliza Hall Institute Of Medical Research |
Molecules which bind clec9a
|
|
EP2858722B8
(en)
|
2012-06-08 |
2018-02-21 |
Aduro BioTech, Inc. |
Compostions and methods for cancer immunotherapy
|
|
US9695212B2
(en)
|
2012-12-13 |
2017-07-04 |
Aduro Biotech, Inc. |
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
|
|
US9840533B2
(en)
|
2013-04-29 |
2017-12-12 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for altering second messenger signaling
|
|
WO2014179760A1
(en)
|
2013-05-03 |
2014-11-06 |
The Regents Of The University Of California |
Cyclic di-nucleotide induction of type i interferon
|
|
PE20160080A1
(es)
|
2013-05-18 |
2016-02-21 |
Aduro Biotech Inc |
Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
|
|
WO2014189806A1
(en)
|
2013-05-18 |
2014-11-27 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
|
|
US10176292B2
(en)
|
2013-07-31 |
2019-01-08 |
Memorial Sloan-Kettering Cancer Center |
STING crystals and modulators
|
|
JP2016538344A
(ja)
|
2013-11-19 |
2016-12-08 |
ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ |
癌処置としてのｓｔｉｎｇアゴニストの使用
|
|
CR20160564A
(es)
|
2014-06-04 |
2017-01-20 |
Glaxosmithkline Ip Dev Ltd |
Dinucleótidos cíclicos como moduladores de sting
|
|
EP3546473B1
(en)
|
2014-12-16 |
2025-12-10 |
Kayla Therapeutics |
Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
|
|
WO2016096577A1
(en)
|
2014-12-16 |
2016-06-23 |
Invivogen |
Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
|
|
GB201501462D0
(en)
|
2015-01-29 |
2015-03-18 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
EA035817B1
(ru)
|
2015-03-10 |
2020-08-14 |
Адуро Байотек, Инк. |
Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
|
|
AU2016262823A1
(en)
*
|
2015-05-18 |
2017-12-07 |
Universita' Degli Studi Di Trento |
Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
|
|
KR102222186B1
(ko)
|
2015-08-13 |
2021-03-03 |
머크 샤프 앤드 돔 코포레이션 |
Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
|
|
JP2018534295A
(ja)
|
2015-10-28 |
2018-11-22 |
アドゥロ バイオテック，インク． |
「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法
|
|
NZ746112A
(en)
|
2016-03-18 |
2023-01-27 |
Immune Sensor Llc |
Cyclic di-nucleotide compounds and methods of use
|
|
PT3440076T
(pt)
|
2016-04-07 |
2022-07-29 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterocíclicas úteis como modeladores de proteína
|
|
JP2019510802A
(ja)
|
2016-04-07 |
2019-04-18 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
タンパク質調節物質として有用な複素環アミド
|
|
PE20210255A1
(es)
|
2016-12-01 |
2021-02-10 |
Takeda Pharmaceuticals Co |
Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon)
|
|
IL272786B2
(en)
|
2017-08-25 |
2025-03-01 |
Codiak Biosciences Inc |
Preparation of therapeutic exosomes using membrane proteins
|
|
WO2019099942A1
(en)
|
2017-11-17 |
2019-05-23 |
Codiak Biosciences, Inc. |
Compositions of engineered exosomes and methods of loading luminal exosomes payloads
|
|
CN111655271B
(zh)
*
|
2017-12-28 |
2025-09-23 |
隆萨销售股份公司 |
用于免疫肿瘤学和抗炎疗法的外来体
|
|
CA3093849A1
(en)
|
2018-03-23 |
2019-09-26 |
Codiak Biosciences, Inc. |
Extracellular vesicles comprising sting-agonist
|
|
SMT202200156T1
(it)
|
2018-11-16 |
2022-05-12 |
Codiak Biosciences Inc |
Vescicole extracellulari ingegnerizzate e loro usi
|
|
BR112021018694A2
(pt)
|
2019-03-21 |
2021-11-30 |
Codiak Biosciences Inc |
Vesículas extracelulares para distribuição de vacina
|